HKIAC

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Retrieved on: 
Jeudi, mars 28, 2024
Agreement, Transplant, CASI Pharmaceuticals, CASI, Patient, Travel, PTCL, Immunoglobulin G, CMC, Depreciation, Bone marrow, Therapy, VCP, Marketing, Research, Cleave, Pralatrexate, MCL, Rituximab, AML, Pembrolizumab, Trial of the century, Myelodysplastic syndrome, Melphalan, MDS, Clinical trial, Follicular lymphoma, Republic, Multiple myeloma, Acute myeloid leukemia, Annual report, National Medical Products Administration, Haematopoietic system, FDA, Cayman, CD19, NMPA, COVID-19, CTA, HKIAC, NHL, Non-Hodgkin lymphoma, MICL, Pharmaceutical industry

BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.

Key Points: 
  • BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
  • CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA®, 33% lower than the same period in 2022.
  • 2023 marks a major milestone for CASI and our partner Juventas; Inaticabtagene Autoleucel (CNCT-19 CAR-T cell therapy) was approved by National Medical Products Administration (NMPA) in November 2023.
  • As of December 31, 2023, CASI had cash, cash equivalents and short term investment of $29.1 million compared to $48.6 million as of December 31, 2022.

Coinllectibles inaugural Web 5.0 Conference focused on real life applications and ownership in the centralised Web 2.0 and decentralised Web 3.0 ecosystems

Retrieved on: 
Mardi, novembre 15, 2022
Cosmos, Commerce, Lawyer, 3D, Dots, Technology, Conference, NFT, Government, ESG, DOT, Auction, Annual report, Partnership, Industry, Blockchain, HKIAC, Ownership, Centralisation, U.S. Securities and Exchange Commission, Adoption, CEO, Web 2.0, Risk, COSG, Comment, Art, OTC, Form 10-K, Cryptocurrency, Online shopping, PRC

Toby O'Connor, CEO of Coinllectiblesshared, "The event sought to add perspectives to the developments in centralised Web 2.0 and decentralised Web 3.0.

Key Points: 
  • Toby O'Connor, CEO of Coinllectiblesshared, "The event sought to add perspectives to the developments in centralised Web 2.0 and decentralised Web 3.0.
  • There were also a lot of practical and fun direct application of technology in areas of art, collectibles and ESG and film."
  • Chai Kok Young, Chief Technology Officer of Coinllectiblesadded, "Coinllectibles has always focused on the usage of blockchain technology to provide a legally-binding digital ownership token (DOT) to a tangible or intangible collectible.
  • For more information on the highlights of the Web 5.0 Conference, Coinllectibles and its DOT offerings, please visit www.coinllectibles.art .

Wolters Kluwer Announces Extension of Kluwer Arbitration's Partnership with Hong Kong International Arbitration Centre

Retrieved on: 
Mercredi, juin 22, 2022
Solution, Merchant International Group, ADR, HKIAC, Technology, Hong Kong International Arbitration Centre, Compliance, Institute, Euronext Amsterdam, Accounting, ITA, ADR Institute of Alberta, Wolters Kluwer, Journalist, General manager, Partnership, Euronext, AEX, American, Collection, Organization, International Group, Risk, WKL, Practice of law, Risk management

NEW YORK, June 22, 2022 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced the extension to Kluwer Arbitration's partnership with Hong Kong International Arbitration Centre (HKIAC), now providing users with access to materials that have been selected from HKIAC Case Digest. The materials provided by HKIAC to Wolters Kluwer under this agreement are available only on Kluwer Arbitration or the HKIAC Case Digest.

Key Points: 
  • NEW YORK, June 22, 2022 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced the extension to Kluwer Arbitration's partnership with Hong Kong International Arbitration Centre (HKIAC), now providing users with access to materials that have been selected from HKIAC Case Digest.
  • The materials provided by HKIAC to Wolters Kluwer under this agreement are available only on Kluwer Arbitration or the HKIAC Case Digest.
  • Through Wolters Kluwer's collaboration with the Institute for Transnational Arbitration (ITA), the HKIAC will make summaries of procedural decisions from HKIAC Case Digest available on Kluwer Arbitration's platform.
  • The Hong Kong International Arbitration Centre is a company limited by guarantee and a non-profit organization established under Hong Kong law.